To assess acquisition of anoikis resistance, we selected mutated KRAS (G12V) and BRAF (V600E) oncogenes owing to their clinical and biological relevance in colorectal adenocarcinoma. This evidence concerns the gene BRAF and colorectal adenocarcinoma.